The story of copyright's flagship drug presents a interesting case for stakeholders in the medicinal sector. While initially a blockbuster success, producing huge profits, the exclusivity lapse and the subsequent entry https://pharma165304.bloggazzo.com/40467082/the-little-copyright-and-big-pharma-a-risky-play